Abstract:Objectives Sustained alcohol abuse initiates a progressive disease pathogenesis involving simple steatosis, steatohepatitis, fibrosis, cirrhosis, and in some cases hepatocellular carcinoma. There is mounting evidence that microbes resident in the human intestine represent a key transmissible factor promoting inflammatory diseases including alcoholic liver disease (ALD). However, mechanisms by which gut microbiota synergize with excessive alcohol intake to promote ALD are poorly understood. We have recently revealed a metaorganismal pathway where nutrients in high fat foods can be metabolized by gut microbes to generate trimethylamine (TMA), which is subsequently metabolized by the host enzyme flavin‐containing monooxygenase 3 (FMO3) to produce the pro‐atherogenic metabolite trimethylamine‐N‐oxide (TMAO). Hepatic FMO3 mRNA levels are suppressed in alcoholics and breath levels of TMA correlate with the severity of alcoholic hepatitis. Thus, this study investigates whether pharmacological inhibition of gut microbe‐derived TMA production can blunt ethanol‐induced liver injury Methods and Results We first determined if ethanol feeding would alter circulating TMA and TMAO levels in mice. Acute (6% vol/vol Lieber DiCarli) and chronic (25 days Lieber DiCarli) isocaloric pair‐ and ethanol‐feeding elicited increases in both TMA and TMAO levels. We then employed a novel approach to block TMA production by using a small molecule inhibitor (CC08) targeting the gut microbial TMA‐producing enzyme CutC/D. CC08 treatment effectively abolished ethanol‐elicited increases in TMA and TMAO. In parallel, CC08 treated mice were completely protected against ethanol‐induced hepatic fat deposition, hepatocellular inflammation, and elevated alanine aminotransferase levels. Collectively, these results suggest inhibiting gut microbial production of TMA can blunt ethanol‐induced liver injury. Conclusions Our results establish the TMA/TMAO pathway as an important regulator of ethanol‐induced liver injury. Inhibition of TMA production by utilizing small molecule inhibitors targeting the TMA lyase, such as CC08, may represent a novel therapeutic approach to combat ethanol‐induced liver injury. Support or Funding Information P50 (AA024333‐01)

Alcohol-dependent Downregulation of Apolipoprotein H Exacerbates Fatty Liver and Gut Microbiota Dysbiosis in Mice

Apolipoprotein H deficiency exacerbates alcohol-induced liver injury via gut Dysbiosis and altered bile acid metabolism

Metabolomics Reveals Gut Microbiota Contribute to PPARα Deficiency-Induced Alcoholic Liver Injury

Intestinal HIF-1α Deletion Exacerbates Alcoholic Liver Disease by Inducing Intestinal Dysbiosis and Barrier Dysfunction

Effects of apolipoprotein H downregulation on lipid metabolism, fatty liver disease, and gut microbiota dysbiosis

Role of Hypoxia Inducing Factor-1β in Alcohol-Induced Autophagy, Steatosis and Liver Injury in Mice

Hepatic Peroxisome Proliferator-Activated Receptor Gamma Signaling Contributes to Alcohol-Induced Hepatic Steatosis and Inflammation in Mice

Chronic Alcohol Exposure Stimulates Adipose Tissue Lipolysis in Mice

Decrease in acetyl-CoA pathway utilizing butyrate-producing bacteria is a key pathogenic feature of alcohol-induced functional gut microbial dysbiosis and development of liver disease in mice

Hepatocyte-derived Fetuin-A promotes alcohol-associated liver disease in mice by inhibiting autophagy-lysosome degradation of TLR and M2 macrophage polarization

HAO1 negatively regulates liver macrophage activation via the NF-κB pathway in alcohol-associated liver disease

OVEREXPRESSION OF ALDEHYDE DEHYDROGENASE‐2 ATTENUATES CHRONIC ALCOHOL EXPOSURE‐INDUCED APOPTOSIS, CHANGE IN Akt AND Pim SIGNALLING IN LIVER

Leptin Deficiency Contributes to the Pathogenesis of Alcoholic Fatty Liver Disease in Mice.

Saturated Dietary Fat Prevented Unsaturated Fat and Alcohol‐mediated Alterations in Gut Microbiota Resulting in Attenuation of Intestinal Barrier Disruption and Liver Injury in an Animal Model of Alcoholic Liver Disease (822.9)

Dysregulated meta-organismal metabolism of aromatic amino acids in alcohol-associated liver disease

Hepatocyte-derived Fetuin-A Promotes Alcohol-Associated Liver Disease in Mice by Inhibiting Autophagy-Lysosome Degradation of TLR4 and M2 Macrophage Polarization

Ethanol Administration Exacerbates the Abnormalities in Hepatic Lipid Oxidation in Genetically Obese Mice

Inhibition of Sphingosine‐1‐Phosphate‐Induced Th17 Cells Ameliorates Alcohol‐Associated Steatohepatitis in Mice

Drugging the Gut Microbiome for the Treatment of Alcohol‐Induced Liver Injury

Loss of hepatic DRP1 exacerbates alcoholic hepatitis by inducing megamitochondria and mitochondrial maladaptation

Hepatic Overproduction of 13-HODE Due to ALOX15 Upregulation Contributes to Alcohol-Induced Liver Injury in Mice